Compare · Mitochondrial peptide
MOTS-c vs SS-31
Both are mitochondrial peptide compounds. Here's how they line up on the evidence — graded the same way.
| MOTS-c | SS-31 | |
|---|---|---|
| Evidence | 3/10 | 6/10 |
| Class | Mitochondrial peptide | Mitochondrial peptide |
| Summary | MOTS-c is a mitochondrial peptide with strong rodent metabolic data but no completed, published human efficacy trial. It's unapproved and WADA-banned. | Elamipretide won a narrow FDA accelerated approval for Barth syndrome in 2025, but its largest trials in myopathy, heart failure, and dry AMD all missed. |
| Full profile → | Full profile → |
MOTS-c
MOTS-c is one of the most hyped "exercise in a vial" peptides, and the biology behind it is genuinely interesting. But as of mid-2026, there's essentially no human evidence that it actually does anything useful.
SS-31
SS-31, now approved as the drug elamipretide, is one of the more useful case studies on this site. It isn't some mystery ingredient dreamed up by supplement marketers — it's a genuine molecule that went through real, careful clinical trials. The honest lesson lies in what those trials found: in its…